Source: ERJ Open Res, 4 (1) 00083-2017; 10.1183/23120541.00083-2017
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Melissa Milan, Silvia Benvenuti, Alice Maria Balderacchi, Anna Rita Virzì, Alessandra Gentile, Rebecca Senetta, Paola Cassoni, Paolo Maria Comoglio, Giulia Maria Stella. RON tyrosine kinase mutations in brain metastases from lung cancer. ERJ Open Res, 4 (1) 00083-2017; 10.1183/23120541.00083-2017

Member's Comments

No comment yet.

Related content which might interest you: A temporal effect of EGFR tyrosine kinase inhibitor in lymphoepithelioma-like carcinoma of lung Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012 EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017 Year: 2017 RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer Source: Eur Respir J 2012; 39: 677-684 Year: 2012 The prediction of risk factors of tyrosine kinase inhibitor-induced pneumonitis in non-small cell lung cancer Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis Source: Eur Respir J 2013; 41: 417-424 Year: 2013 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015 EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up Source: Eur Respir J 2009; 33: 436-440 Year: 2009 Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors Source: ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016 Year: 2017 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 366-372 Year: 2012 CREB signaling in KRAS-driven lung adenocarcinoma Source: ERS Lung Science Conference 2017 Year: 2017 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 Radiation/cisplatin/vinorelbine therapy increase p53 protein phosphorylated at serine 392 in recurrent primary squamous cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 17s Year: 2001 Croatian Caucasians with lung adenocarcinoma harbouring EGFR mutations with and without brain metastasis Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Nonsmall cell lung cancer Source: Eur Respir Rev 2013; 22: 33-36 Year: 2013 Prognostic significance and correlation between Akt phosphorylation and loss of PTEN protein expression in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 458s Year: 2005 Oncogenic potential of MET SEMA mutations affecting brain metastases from NSCLC is sustained by their microrheological features Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017 K-RAS oncogenic mutations in patients with nonsmall cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007